On October 7, 2019 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that the company will host its inaugural Analyst and Investor Day on Monday, November 18, 2019, at the Nasdaq Marketsite, 4 Times Square, 10th Floor, New York, NY (Press release, Surface Oncology, OCT 7, 2019, View Source [SID1234540079]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Formal presentations will take place from 8:00 a.m-11:00 a.m. ET, followed by questions and answers from the full panel of presenters. Presentations will cover a variety of topics, including:
Corporate overview and strategic update: Jeff Goater, chief executive officer of Surface Oncology
Keynote presentation by Dr. E. John Wherry: Emerging trends in T cell exhaustion and immunotherapy of cancer
Overview and update of SRF617, a novel, potential best-in-class anti-CD39 antibody: Robert Ross, M.D., chief medical officer of Surface Oncology
CD39 is an enzyme critical to both the production of immunosuppressive adenosine and the breakdown of pro-inflammatory adenosine triphosphate (ATP).
Overview and update of SRF388, a first-in-class antibody targeting IL-27: Vito Palombella, Ph.D., chief scientific officer of Surface Oncology
IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Elevated levels of IL-27 and IL-27 induced gene expression signatures have been identified in certain types of cancer.
Introduction to Surface’s first natural killer (NK) cell targeting program, SRF813, a highly differentiated approach to targeting CD112R: Pamela Holland, Ph.D., vice president of biology at Surface Oncology
CD112R is a recently identified immune checkpoint protein that contributes to both T cell and NK cell suppression through its role as an inhibitory receptor. Blockade of CD112R promotes antitumor responses through innate and adaptive arms of the immune system.
A live webcast of the Analyst and Investor Day will be available on the Surface Oncology website at View Source
About Dr. John Wherry:
E. John Wherry, Ph.D., is the Richard and Barbara Schiffrin President’s Distinguished Professor, chair of the Department of Systems Pharmacology and Translational Therapeutics, and director of the Penn Institute for Immunology at the Perelman School of Medicine at the University of Pennsylvania. He is the co-director of the Parker Institute for Cancer Immunotherapy at Penn, as well as a member of the Scientific Advisory Board of Surface Oncology. His research has focused on T cell exhaustion in chronic viral infections and cancer. His work has defined the developmental biology and molecular regulation of
T cell exhaustion, role of checkpoints including PD-1, LAG-3 and others and significantly informed the development of immunotherapies for human cancer.